ProMetic Life Sciences Inc. (TSE:PLI) Director Pierre Laurin sold 82,738 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of C$1.45, for a total value of C$119,970.10.

Pierre Laurin also recently made the following trade(s):

  • On Wednesday, September 13th, Pierre Laurin sold 82,738 shares of ProMetic Life Sciences stock. The stock was sold at an average price of C$1.44, for a total value of C$119,142.72.
  • On Thursday, September 7th, Pierre Laurin sold 41,427 shares of ProMetic Life Sciences stock. The stock was sold at an average price of C$1.45, for a total value of C$60,069.15.

ProMetic Life Sciences Inc. (TSE:PLI) traded down 1.38% during trading on Friday, hitting $1.43. 2,102,143 shares of the company’s stock traded hands. The company’s 50 day moving average is $1.43 and its 200-day moving average is $1.88. The stock’s market cap is $1.01 billion. ProMetic Life Sciences Inc. has a 12 month low of $1.12 and a 12 month high of $3.24.

ILLEGAL ACTIVITY NOTICE: “ProMetic Life Sciences Inc. (PLI) Director Pierre Laurin Sells 82,738 Shares” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/15/prometic-life-sciences-inc-pli-director-pierre-laurin-sells-82738-shares.html.

A number of research analysts have recently commented on the company. Canaccord Genuity dropped their price target on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating for the company in a research note on Monday, June 19th. Royal Bank Of Canada decreased their price objective on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating for the company in a report on Wednesday, August 16th. National Bank Financial increased their price objective on ProMetic Life Sciences from C$2.00 to C$2.50 in a report on Wednesday, August 30th. Scotiabank decreased their price objective on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating for the company in a report on Friday, July 7th. Finally, TD Securities decreased their price target on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a report on Wednesday, August 16th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of C$3.60.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Insider Buying and Selling by Quarter for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.